Клиническая инфектология и паразитология · Sep 21, 2026
Noninfectious comorbid diseases in HIV-infected patients receiving virologically effective antiretroviral therapy
By Козорез ЕИ, Демчило АП, С. СК et al.
INTRODUCTION: HIV-infected patients are at higher risk of premature aging and the early development of age-associated comorbid diseases (КЗ). OBJECTIVE: To assess the prevalence and structure of noninfectious КЗ in HIV-infected patients receiving virologically effective antiretroviral therapy. MATERIALS AND METHODS: Concomitant noninfectious diseases were analyzed in 551 HIV-infected patients aged 40 to 69 years with an undetectable viral load while receiving antiretroviral therapy. RESULTS: The most important noninfectious КЗ in HIV-infected patients with an undetectable viral load were atherosclerotic cardiovascular diseases, which were diagnosed in 15.6% of patients aged 40–49 years, 33.1% of those aged 50–59 years, and 71.4% of those aged 60–69 years; severe neurocognitive disorders were detected in 8.8% of patients aged 40–49 years, 23.8% of those aged 50–59 years, and 26.2% of those aged 60–69 years; degenerative-dystrophic diseases of the bone and joint system were detected in 13.8% 18.5%, 19.1%, respectively. In HIV-infected patients with a CD4 lymphocyte count of less than 500 cells/μL, the odds of developing neurocognitive disorders (p=0.001) and liver cirrhosis (p=0.023) were significantly higher. Non-AIDS-defining malignant neoplasms (p=0.014) were recorded more frequently in those with a history of a CD4 lymphocyte count of less than 50 cells/μL. A combination of two or more noninfectious КЗ was present in 14.9% of patients aged 40–49 years, 26.4% of those aged 50–59 years, and 47.6% of those aged 60–69 years. A combination of two or more noninfectious КЗ in HIV-infected patients was recorded more frequently with a CD4 lymphocyte count of less than 500 cells/μL (p=0.001), at stage 4 of HIV (p=0.01), and in women (p=0.01). CONCLUSIONS: The high prevalence of noninfectious age-associated diseases in HIV-infected patients necessitates multidisciplinary collaboration and a personalized approach when choosing treatment and prevention strategies. Immunologically and virologically effective antiretroviral therapy is critically important for preventing premature aging and ensuring quality medical care for patients living with HIV. Introduction. HIV-infected patients are at higher risk of premature aging and early development of age-associated comorbidities. Purpose. To assess the prevalence and structure of non-infectious diseases in HIV-infected patients receiving virologically effective antiretroviral therapy. Materials and methods. The analysis included concomitant non-communicable diseases in 551 HIV-infected patients with undetectable viral load receiving antiretroviral therapy aged 40 to 69 years. Results. The most important non-infectious cardiovascular diseases in HIV-infected patients with undetectable viral load were atherosclerotic cardiovascular diseases, which were diagnosed in 15.6% of patients aged 40–49 years, 33.1% of those aged 50–59 years, and 71.4% of those aged 60–69 years; severe neurocognitive disorders were detected in 8.8% of patients aged 40–49 years, 23.8% of those aged 50–59 years, and 26.2% of those aged 60–69 years; degenerative-dystrophic diseases of the bone and joint system – in 13.8%, 18.5%, and 19.1%, respectively. In HIV-infected patients with a CD4 lymphocyte level of less than 500 cells/μl, the chances of developing neurocognitive disorders (p=0.001) and liver cirrhosis (p=0.023) were significantly higher. With a CD4 lymphocyte level of less than 50 cells/μl, non-AIDS-defining malignant neoplasms (p=0.014) were registered more often in anamnesis. The combination of two or more non-infectious congenital malignancies was observed in 14.9% of patients aged 40–49, 26.4% in those aged 50–59, and 47.6% in those aged 60–69. The combination of two or more non-infectious congenital malignancies in HIV-infected patients was registered more often with a CD4 lymphocyte level of less than 500 cells/μl (p=0.001), at stage 4 of HIV (p=0.01), and in women (p=0.01). Conclusion. The high prevalence of non-communicable age-associated diseases in HIV-infected patients necessitates multidisciplinary collaboration and a personalized approach when choosing treatment and prevention strategies. Immunologically and virologically effective antiretroviral therapy is critical for preventing premature aging and ensuring quality medical care for patients living with HIV.